USANA Health Sciences Inc. - 10-K Summary (Fiscal Year Ended Jan 1, 2005)
Business Context and Reporting Period
Company: USANA Health Sciences, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended January 1, 2005 (52-week year)
Business Model: USANA develops, manufactures, and distributes science-based nutritional and personal care products primarily through a network marketing system using independent "Associates." It also sells directly to "Preferred Customers" and operates a Contract Manufacturing segment.
Key Financial Metrics
| Metric | Fiscal 2004 | Fiscal 2003 | Change |
|---|---|---|---|
| Net Sales | $272.8 million | $200.0 million | +36.4% |
| Gross Profit | $206.0 million | $155.6 million | +32.4% |
| Gross Margin | 75.5% | 77.8% | -2.3 pts |
| Net Earnings | $30.8 million | $20.8 million | +48.1% |
| Diluted EPS | $1.51 | $0.98 | +54.1% |
| Operating Cash Flow | $38.2 million | $35.5 million | +7.6% |
| Cash & Equivalents | $15.1 million | $19.0 million | -20.5% |
| Long-Term Debt | $0 | $0 | N/A |
| Working Capital | $18.1 million | $18.3 million | -1.1% |
Segment Performance: The Direct Selling segment accounted for 96.2% of net sales ($262.5 million). The Contract Manufacturing segment contributed 3.8% ($10.3 million).
Material Changes vs. Prior Period
- Revenue Growth: Driven by an 18% increase in active Associates and a 22% increase in Preferred Customers in established markets, plus new market openings in Mexico (March 2004) and full-year contributions from South Korea and Singapore.
- Margin Compression: Consolidated gross margin decreased to 75.5% from 77.8%. This was primarily due to higher raw material costs for Coenzyme Q10 (CoQ10) and increased inventory valuation provisions for obsolete Sensé products. The Contract Manufacturing segment margin dropped significantly to 12.5% due to facility upgrades and expedited freight costs.
- Expense Management: Selling, General, and Administrative (SG&A) expenses decreased as a percentage of sales to 20.0% (from 22.2%) due to operating leverage, though absolute costs rose $10.3 million to support expansion.
- Share Repurchases: The company spent approximately $34.9 million repurchasing common stock, which reduced cash balances and contributed to the decrease in working capital.
Guidance, Outlook, and Risks
- 2005 Guidance: Management anticipates annual net sales in the range of $319 million to $327 million for fiscal year 2005.
- Strategic Focus: Plans to enter one additional international market in 2005 and continue expanding the Associate base through "Health & Freedom Thursdays" and new sales tools.
- Key Risks:
- Regulatory: Network marketing is subject to intense scrutiny; violations by Associates or changes in laws (e.g., FDA, FTC) could materially impact operations.
- Supply Chain: Shortages and price increases for raw materials like CoQ10 may pressure margins.
- Foreign Exchange: Approximately 54.6% of sales are international; a strengthening U.S. dollar could negatively impact reported earnings.
- Associate Turnover: Revenue is dependent on the recruitment and retention of independent Associates, which involves high turnover.
Investor Verification Checklist
- Associate Activity: Verify the sustainability of the 29.5% growth in active Associates and the retention rates in new markets (Mexico, Singapore, South Korea).
- Raw Material Costs: Monitor the resolution of CoQ10 supply shortages and the impact on gross margins in 2005.
- Contract Manufacturing Concentration: Note that 77% of Contract Manufacturing revenue comes from a single customer; assess the stability of this relationship.
- Cash Utilization: Review the balance between aggressive share repurchases ($34.9M in 2004) and capital requirements for international expansion.
- Regulatory Compliance: Monitor any new FTC or FDA actions regarding network marketing practices or dietary supplement labeling that could affect the business model.